Protagenic Therapeutics (PTIX) 10-Q 8 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 07, 2017
Document Information [Line Items]
Entity Registrant Name	Protagenic Therapeutics, Inc.\new
Entity Central Index Key	1,022,899
Trading Symbol	ptix
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		10,261,419
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 627,825	$ 3,100,398
Marketable securities	1,825,923
Prepaid expenses		60,417
TOTAL CURRENT ASSETS	2,453,748	3,160,815
EQUIPMENT - NET	1,160	1,097
TOTAL ASSETS	2,454,908	3,161,912
CURRENT LIABILITIES
Accounts payable and accrued expenses	73,812	167,987
Derivative liability	504,326	516,870
TOTAL CURRENT LIABILITIES	578,138	684,857
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred stock
Common stock, $.0001 par value, 100,000,000 shares authorized, 10,261,419 shares issued and outstanding at June 30, 2017, 10,261,419 shares issued and outstanding at December 31, 2016	1,026	1,026
Additional paid-in-capital	11,740,663	11,239,786
Accumulated deficit	(9,691,068)	(8,582,123)
Accumulated other comprehensive loss	(173,852)	(181,635)
TOTAL STOCKHOLDERS' EQUITY	1,876,770	2,477,055
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	2,454,908	3,161,912
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY
Preferred stock	$ 1	$ 1

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Preferred stock, shares undesignated (in shares)	2,000,000	2,000,000
Preferred stock, par value (in dollars per share)	$ 0.000001	$ 0.000001
Preferred stock, shares authorized (in shares)	18,000,000	18,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	10,261,419	10,261,419
Common stock, shares outstanding (in shares)	10,261,419	10,261,419
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.000001	$ 0.000001
Preferred stock, shares authorized (in shares)	18,000,000	18,000,000
Preferred stock, shares issued (in shares)	872,766	872,766
Preferred stock, shares outstanding (in shares)	872,766	872,766

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
REVENUE	$ 0	$ 0	$ 0	$ 0
OPERATING AND ADMINISTRATIVE EXPENSES
Research and development	120,180	290,577	258,992	227,812
General and administrative	351,409	206,079	870,517	590,417
Goodwill impairment			0	404,169
TOTAL OPERATING AND ADMINISTRATIVE EXPENSES	471,589	496,656	1,129,509	1,222,398
LOSS FROM OPERATIONS	(471,589)	(496,656)	(1,129,509)	(1,222,398)
OTHER (EXPENSE) INCOME
Interest income	7,928	279	8,112	279
Interest expense - stockholder		(1,767)		(7,162)
Realized loss on foreign exchange transactions		543		(6,599)
Realized loss on marketable securities	(92)		(92)
Change in fair value of derivative liability	12,661	(26,887)	12,544	(28,394)
TOTAL OTHER (EXPENSE) INCOME	20,497	(27,832)	20,564	(41,875)
NET LOSS	(451,092)	(524,488)	(1,108,945)	(1,264,273)
COMPREHENSIVE LOSS
Net unrealized loss on marketable securities	(3,163)		(3,163)
Foreign exchange translation gain	8,916	21,868	10,946	22,292
TOTAL COMPREHENSIVE LOSS	$ (445,339)	$ (502,620)	$ (1,101,162)	$ (1,241,981)
Net loss per share - Basic and Diluted (in dollars per share)	$ (0.04)	$ (0.08)	$ (0.11)	$ (0.71)
Weighted average common shares - Basic and Diluted (in shares)	10,261,419	6,612,838	10,261,419	1,781,338

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (1,108,945)	$ (1,264,273)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	(25)	234
Goodwill impairment	0	404,169
Stock based compensation	500,877	239,865
Accretion to bridge loan		7,162
Legal fees satisfied through issuance of Series B preferred stock		150,000
Change in fair value of the derivative liability	(12,544)	28,394
Loss on sale of marketable securities	92
Changes in operating assets and liabilities
Prepaid expenses	60,417
Other receivables		6,428
Other assets
Accounts payable and accrued expenses	44,148	74,422
NET CASH USED IN OPERATING ACTIVITIES	(604,276)	(502,443)
CASH FLOWS USED IN INVESTING ACTIVITIES
Sale of marketable securities	720,000
Purchase of marketable securities	(2,549,179)
NET CASH USED IN INVESTING ACTIVITIES	(1,829,179)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from bridge loan		19,000
NET CASH PROVIDED BY FINANCING ACTIVITIES		4,302,437
Effect of exchange rate on cash and cash equivalents	(39,118)	(15,148)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(2,472,573)	3,784,846
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	3,100,398	3,343
CASH AND CASH EQUIVALENTS, END OF PERIOD	627,825	3,788,189
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest expense
Cash paid for income taxes
NONCASH TRANSACTIONS
Unrealized loss on marketable securities	3,163
Warrants issued to placement agent		146,641
Warrants issued for Atrinsic debt settlement and conversion		340,784
Debt settled with issuance of Series B preferred stock		425,265
Reclassification of warrants to derivative liabilities from equity		487,425
Goodwill recognized in connection with reverse business combination		404,169
Accrued liabilities paid through the issuances of Series B preferred stock		125,000
Series B Preferred Stock [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of Series B Preferred Stock		$ 4,283,437

Note 1 - Organization and Natur

Note 1 - Organization and Nature of Business	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1 ORGANIZATION AND NATURE OF BUSINESS Company Background Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”) is a Delaware corporation with one 2006 2006 The Company was formerly known as Atrinsic, Inc., a company that, in 2013, 11 February 12, 2016, June 17, 2016, The Company is a biotechnology company focused on the discovery, research and development of pre-clinical studies for developing novel, naturally occurring, human neuropeptide-based, brain-active therapeutics for treatment of depression, mood, anxiety and other neurodegenerative disorders. The Company is also interested in acquiring exclusive intellectual property rights for peptide-based therapeutics for the treatment of neurological and mood disorders.

Note 2 - Liquidity

Note 2 - Liquidity	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Liquidity and Going Concern [Text Block]	NOTE 2 The Company continually projects anticipated cash requirements, predominantly from the ongoing funding requirements of our neuropeptide drug development program. The majority of these expenses relate to paying external vendors such as Contract Research Organizations (CROs) and peptide synthesizer companies. They could also include business combinations, capital expenditures, and new drug development working capital requirements. As shown in the accompanying consolidated condensed financial statements, the Company incurred a net loss of $1,108,945 $1,264,273 six June 30, 2017 2016, $9,691,068 June 30, 2017. $1,875,610 June 30, 2017. third 2018. third 2018.

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 3 SUMMARY OF SIGNFICANT ACCOUNTING POLICIES Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the SEC for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended June 30, 2017 2016. not not The condensed consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly-owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2016, December 31, 2016 2015 10 May 8, 2017. six June 30, 2017 not December 31, 2017 Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the consolidated financial statements include the allocation of the fair value of acquired assets and liabilities associated with the Merger, income tax provisions, impairment of goodwill, valuation of stock options and warrants and assessment of deferred tax asset valuation allowance. Reclassification Certain prior period amounts have been reclassified to conform to current period presentation. Concentrations of Credit Risk The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three June 30, 2017 December 31, 2016, not Marketable Securities The Company accounts for marketable debt and equity securities, available for sale, in accordance with sub-topic 320 10 320 10” Pursuant to Paragraph 320 10 35 1, 815 25 35 1 815 25 35 4. During the six June 30, 2017 $2,549,179 $720,000 $92 $3,163. June 30, 2017, $1,825,923. Goodwill Goodwill represents the excess of the purchase price over the fair value of the assets acquired and liabilities assumed. The Company is required to perform impairment reviews annually and more frequently in certain circumstances. The Company performs the annual assessment on December 31. In accordance with ASC 350–20 Goodwill not not not not Atrinsic’s assets and liabilities acquired in the Merger had a minimal value therefore the Company recorded the fair value of shares given to predecessor stockholders as goodwill. Immediately subsequent to the merger the Company fully impaired the goodwill. The allocation of the consideration transferred is as follows: Shares issued in connection with Merger: Atrinsic 25,867 shares Common stock $ 32,334 Atrinsic Series A preferred stock as converted to Series B preferred stock, 297,468 shares 371,835 Total value of shares issued to Atrinsic on Merger 404,169 Fair value of net assets identified - Goodwill 404,169 Net value of consideration $ - Goodwill impairment for the year ended December 31, 2016 $404,169. June 30, 2017, $0. Fair Value Measurements ASC 820, not 820 three 1 3 The three Level 1 Level 2 not Level 3 The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short maturity of those instruments. Transactions involving related parties cannot be presumed to be carried out on an arm's-length basis, as the requisite conditions of competitive, free-market dealings may not not The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value as of June 30, 2017. Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Marketable securities 1,825,923 — 1,825,923 — 1,825,923 Derivative warrants liabilities $ (504,326 ) $ — $ — $ (504,326 ) $ (504,326 ) The following table provides a summary of financial instruments that are measured at fair value as of December 31, 2016. Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative warrants liabilities $ (516,870 ) $ — $ — $ (516,870 ) $ (516,870 ) The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3 June 30, 2017: Fair Value Measurement Using Level 3 Inputs Total Balance, December 31, 2016 $ 516,870 Change in fair value of derivative warrants liabilities (12,544 ) Balance, June 30, 2017 $ 504,326 The fair value of the derivative feature of the 127,346 295,945 February 12, 2016 December 31, 2016 June 30 , 2017 Exercise price $ 1.25 $ 1.25 $ 1.25 Risk free interest rate 1.20 % 1.93 % 1.89 % Dividend yield 0.00 % 0.00 % 0.00 % Expected volatility 156 % 219 % 258.4 % Contractual term (in years) 5.0 4.25 3.5 Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar expected term on the date of the grant. Dividend yield: The Company uses a 0% not not Volatility: The Company calculates the expected volatility of the stock price based on the corresponding volatility of the Company’s peer group stock price for a period consistent with the warrants’ contractual term. Contractual term: The Company’s contractual term is based on the remaining contractual maturity of the warrants. The use of a Monte Carlo or lattice model for these calculations would not During the six June, 2017 2016, $12,544 $28,394, Derivative Liability The Company evaluates its options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815 10 05 4 815 40 25. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative liabilities will be classified in the balance sheet as current or non-current based on whether or not 12 Stock-Based Compensation The Company accounts for stock based compensation costs under the provisions of ASC 718, 718. 718 Stock-Based Compensation for Non-Employees The Company accounts for warrants and options issued to non-employees under ASC 505 50, Equity – Equity Based Payments to Non-Employees, Basic and Diluted Net (Loss) per Common Share Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. Potentially Outstanding Dilutive Common Shares For the Six Months Ended June 30, 2017 For the Six Months Ended June 30, 2016 Conversion Feature Shares Common shares issuable under the conversion feature of preferred shares 872,766 11,018,766 Stock Options 2,613,299 2,592,229 Warrants 3,726,658 3,826,658 Total potentially outstanding dilutive common shares 7,212,723 17,437,653

Note 4 - Accounts Payable and A

Note 4 - Accounts Payable and Accrued Expenses	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 4 ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consist of the following at: June 30 , 2017 December 31, 2016 Legal $ - $ 1,190 Accounting 13,222 - Patent expense - 37,142 Research and development 30,970 116,255 Other 29,620 13,400 $ 73,812 $ 167,987

Note 5 - Derivative Liabilities

Note 5 - Derivative Liabilities	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 5 Upon closing of the private placement transactions on February 12, 2016, 127,346 295,945 $1.25 five

Note 6 - Stockholders' Equity

Note 6 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 6 STOCKHOLDERS’ EQUITY Stock-Based Compensation In connection with the consummation of the Merger completed on February 12, 2016, 2006 “2006 June 17, 2016, 2016 “2016 2006 not 2006 2006 2006 Pursuant to the 2016 may On January 1, 2017, 2016 564,378 January 1, 2017, 2016 2,712,678. 2016 10 As of December 31, 2016, 2,484,445 2006 2016 Exercise price $ .26 - $1.25 Expected dividend yield 0% Risk free interest rate 1.01% - 2.43% Expected life in years 5 Expected volatility 85% - 213% As of June 30, 2017, 2,613,299 2006 2016 Exercise price $ 1.00 - $1.25 Expected dividend yield 0% Risk free interest rate 1.89% - 2.31% Expected life in years 4.60 - 9.59 Expected volatility 204% - 258% The following is an analysis of the stock option grant activity under 2006 2016 Weighted Average Weighted Average Exercise Remaining Number Price Life Stock Options Outstanding January 1, 2017 2,484,445 $ 1.18 9.82 Granted 150,000 1.25 4.11 Expired (21,146 ) 1.00 Outstanding June 30, 2017 2,613,299 $ 1.18 7.92 As of June 30, 2017 December 31, 2016, $193,687 $171,537, The total number of options granted during the six June, 2017 2016 2006 0 and 100,000 , respectively. The exercise price for these options was $1.25 The total number of options granted during the six June, 2017 2016 2016 150,000 and 1,201,084 , respectively. The exercise price for these options was $1.25 The Company recognized compensation expense related to options issued of $500,877 $176,892 six June 30, 2017 2016, As of June 30, 2017, $1,033,921. Warrants: In connection with the Merger, all of the issued and outstanding warrants to purchase shares of Prior Protagenic common stock, converted, on a 1 1 New Warrants Simultaneous with the Merger and the Private Offering, New Warrants to purchase 3,403,367 $1.05 $665,000 $35,000 five 295,945 $1.25 127,346 $1.25 423,291 A summary of warrant issuances are as follows: Weighted Average Weighted Average Exercise Remaining Number Price Life Warrants Outstanding January 1, 2017 3,826,658 $ 1.02 5.72 Expired 100,000 1.25 Outstanding June 30, 2017 3,726,658 $ 1.05 5.26 As of June 30, 2017 3,726,658 $1.05 $763,342.

Note 7 - Collaborative Agreemen

Note 7 - Collaborative Agreements	6 Months Ended
	Jun. 30, 2017
In Process Research and Development [Member]
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 7 COLLABORATIVE AGREEMENTS The Company and the University of Toronto (the “University”), a stockholder of the Company, entered into an agreement effective December 14, 2004 ( March 31, 2013. The Company and the University entered into a new agreement effective April 1, 2014 ( February 2017, December 31, 2017, The University has been granted 25,000 $1.00 10 April 1, 2022. 483,299 275,000 $1.00 10 13 March 30, 2021, December 1, 2022, April 15, 2026 March 1, 2027. The sponsorship research and development expenses pertaining to the Research Agreements were $20,233.34 $3,000 June 30, 2017 2016,

Note 8 - Licensing Agreements

Note 8 - Licensing Agreements	6 Months Ended
	Jun. 30, 2017
Licensing Agreements [Member]
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 8 LICENSING AGREEMENTS On July 31, 2005, February 18, 2015 not Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% 10% September 9, 2006, 2.5% no six June 30, 2017 2016 not In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, and the Company fails to respond to notice of such failure from the University within the Cure period, the University may June 30, 2017, may may 2.5% The patent applications were made in the name of the Professor and other inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the six

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 9 Consulting Agreement s The Company had an employment agreement with a former officer (the “Former Officer”) which expired on December 31, 2015. $6,489 75,000 $64,223 $53,519 2015. Upon the expiration of the employment agreement, the Company and Former Officer entered into a consulting agreement in its place, which provides that the Company may 250,000 25,000 225,000 $1.00 $1.25, March 30, 2021, March 1, 2024 March 9, 2025. may not fifteen 15 The Company has accrued $0 $12,800 six June 30, 2017. PTI Canada entered into a consulting agreement with a stockholder of the Company (the “Consultant”) which, which as amended, expires on December 31, 2017. 150,000 $1.00 $1.25, 10 March 30, 2021 March 1, 2025. US$2,370 may not fifteen 15 The Company has accrued $0 US$13,493 six June 30, 2017. Legal Proceedings From time to time we may no

Note 10 - Subsequent Events

Note 10 - Subsequent Events	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 10 SUBSEQUENT EVENTS The Company has evaluated the period after the balance sheet date up through the date that the consolidated financial statements were filed, and determined that there were no

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the SEC for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended June 30, 2017 2016. not not The condensed consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly-owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2016, December 31, 2016 2015 10 May 8, 2017. six June 30, 2017 not December 31, 2017
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the consolidated financial statements include the allocation of the fair value of acquired assets and liabilities associated with the Merger, income tax provisions, impairment of goodwill, valuation of stock options and warrants and assessment of deferred tax asset valuation allowance.
Reclassification, Policy [Policy Text Block]	Reclassification Certain prior period amounts have been reclassified to conform to current period presentation.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three June 30, 2017 December 31, 2016, not
Marketable Securities, Policy [Policy Text Block]	Marketable Securities The Company accounts for marketable debt and equity securities, available for sale, in accordance with sub-topic 320 10 320 10” Pursuant to Paragraph 320 10 35 1, 815 25 35 1 815 25 35 4. During the six June 30, 2017 $2,549,179 $720,000 $92 $3,163. June 30, 2017, $1,825,923.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill Goodwill represents the excess of the purchase price over the fair value of the assets acquired and liabilities assumed. The Company is required to perform impairment reviews annually and more frequently in certain circumstances. The Company performs the annual assessment on December 31. In accordance with ASC 350–20 not not not not Atrinsic’s assets and liabilities acquired in the Merger had a minimal value therefore the Company recorded the fair value of shares given to predecessor stockholders as goodwill. Immediately subsequent to the merger the Company fully impaired the goodwill. The allocation of the consideration transferred is as follows: Shares issued in connection with Merger: Atrinsic 25,867 shares Common stock $ 32,334 Atrinsic Series A preferred stock as converted to Series B preferred stock, 297,468 shares 371,835 Total value of shares issued to Atrinsic on Merger 404,169 Fair value of net assets identified - Goodwill 404,169 Net value of consideration $ - Goodwill impairment for the year ended December 31, 2016 $404,169. June 30, 2017, $0.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements ASC 820, not 820 three 1 3 The three Level 1 Level 2 not Level 3 The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short maturity of those instruments. Transactions involving related parties cannot be presumed to be carried out on an arm's-length basis, as the requisite conditions of competitive, free-market dealings may not not The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value as of June 30, 2017. Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Marketable securities 1,825,923 — 1,825,923 — 1,825,923 Derivative warrants liabilities $ (504,326 ) $ — $ — $ (504,326 ) $ (504,326 ) The following table provides a summary of financial instruments that are measured at fair value as of December 31, 2016. Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative warrants liabilities $ (516,870 ) $ — $ — $ (516,870 ) $ (516,870 ) The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3 June 30, 2017: Fair Value Measurement Using Level 3 Inputs Total Balance, December 31, 2016 $ 516,870 Change in fair value of derivative warrants liabilities (12,544 ) Balance, June 30, 2017 $ 504,326 The fair value of the derivative feature of the 127,346 295,945 February 12, 2016 December 31, 2016 June 30, 2017 Exercise price $ 1.25 $ 1.25 $ 1.25 Risk free interest rate 1.20 % 1.93 % 1.89 % Dividend yield 0.00 % 0.00 % 0.00 % Expected volatility 156 % 219 % 258.4 % Contractual term (in years) 5.0 4.25 3.5 Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar expected term on the date of the grant. Dividend yield: The Company uses a 0% not not Volatility: The Company calculates the expected volatility of the stock price based on the corresponding volatility of the Company’s peer group stock price for a period consistent with the warrants’ contractual term. Contractual term: The Company’s contractual term is based on the remaining contractual maturity of the warrants. The use of a Monte Carlo or lattice model for these calculations would not During the six June, 2017 2016, $12,544 $28,394,
Derivatives, Policy [Policy Text Block]	Derivative Liability The Company evaluates its options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815 10 05 4 815 40 25. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative liabilities will be classified in the balance sheet as current or non-current based on whether or not 12
Compensation Related Costs, Policy [Policy Text Block]	Stock-Based Compensation The Company accounts for stock based compensation costs under the provisions of ASC 718, 718. 718 Stock-Based Compensation for Non-Employees The Company accounts for warrants and options issued to non-employees under ASC 505 50,
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net (Loss) per Common Share Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. Potentially Outstanding Dilutive Common Shares For the Six Months Ended June 30, 2017 For the Six Months Ended June 30, 2016 Conversion Feature Shares Common shares issuable under the conversion feature of preferred shares 872,766 11,018,766 Stock Options 2,613,299 2,592,229 Warrants 3,726,658 3,826,658 Total potentially outstanding dilutive common shares 7,212,723 17,437,653

Note 3 - Summary of Significa17

Note 3 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Shares issued in connection with Merger: Atrinsic 25,867 shares Common stock $ 32,334 Atrinsic Series A preferred stock as converted to Series B preferred stock, 297,468 shares 371,835 Total value of shares issued to Atrinsic on Merger 404,169 Fair value of net assets identified - Goodwill 404,169 Net value of consideration $ -
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Marketable securities 1,825,923 — 1,825,923 — 1,825,923 Derivative warrants liabilities $ (504,326 ) $ — $ — $ (504,326 ) $ (504,326 ) Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative warrants liabilities $ (516,870 ) $ — $ — $ (516,870 ) $ (516,870 )
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair Value Measurement Using Level 3 Inputs Total Balance, December 31, 2016 $ 516,870 Change in fair value of derivative warrants liabilities (12,544 ) Balance, June 30, 2017 $ 504,326
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	February 12, 2016 December 31, 2016 June 30 , 2017 Exercise price $ 1.25 $ 1.25 $ 1.25 Risk free interest rate 1.20 % 1.93 % 1.89 % Dividend yield 0.00 % 0.00 % 0.00 % Expected volatility 156 % 219 % 258.4 % Contractual term (in years) 5.0 4.25 3.5
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially Outstanding Dilutive Common Shares For the Six Months Ended June 30, 2017 For the Six Months Ended June 30, 2016 Conversion Feature Shares Common shares issuable under the conversion feature of preferred shares 872,766 11,018,766 Stock Options 2,613,299 2,592,229 Warrants 3,726,658 3,826,658 Total potentially outstanding dilutive common shares 7,212,723 17,437,653

Note 4 - Accounts Payable and18

Note 4 - Accounts Payable and Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	June 30 , 2017 December 31, 2016 Legal $ - $ 1,190 Accounting 13,222 - Patent expense - 37,142 Research and development 30,970 116,255 Other 29,620 13,400 $ 73,812 $ 167,987

Note 6 - Stockholders' Equity (

Note 6 - Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Exercise price $ .26 - $1.25 Expected dividend yield 0% Risk free interest rate 1.01% - 2.43% Expected life in years 5 Expected volatility 85% - 213% Exercise price $ 1.00 - $1.25 Expected dividend yield 0% Risk free interest rate 1.89% - 2.31% Expected life in years 4.60 - 9.59 Expected volatility 204% - 258%
Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Average Weighted Average Exercise Remaining Number Price Life Stock Options Outstanding January 1, 2017 2,484,445 $ 1.18 9.82 Granted 150,000 1.25 4.11 Expired (21,146 ) 1.00 Outstanding June 30, 2017 2,613,299 $ 1.18 7.92
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Weighted Average Weighted Average Exercise Remaining Number Price Life Warrants Outstanding January 1, 2017 3,826,658 $ 1.02 5.72 Expired 100,000 1.25 Outstanding June 30, 2017 3,726,658 $ 1.05 5.26

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Net Income (Loss) Attributable to Parent	$ (451,092)	$ (524,488)	$ (1,108,945)	$ (1,264,273)
Retained Earnings (Accumulated Deficit)	(9,691,068)		(9,691,068)		$ (8,582,123)
Net Working Capital	$ 1,875,610		$ 1,875,610

Note 3 - Summary of Significa21

Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Fair Value Assumptions, Expected Dividend Rate			0.00%
Derivative, Gain (Loss) on Derivative, Net	$ 12,661	$ (26,887)	$ 12,544	$ (28,394)
Cash Equivalents, at Carrying Value	0		0		$ 0
Payments to Acquire Available-for-sale Securities			2,549,179
Proceeds from Sale of Available-for-sale Securities			720,000
Available-for-sale Securities, Gross Realized Gain (Loss)	(92)		(92)
Available-for-sale Securities, Gross Unrealized Gain (Loss)			(3,163)
Available-for-sale Securities	1,825,923		1,825,923
Goodwill, Impairment Loss			$ 0	$ 404,169	$ 404,169
Private Placement [Member] | Series B Preferred Stock [Member] | Strategic Bio Partners [Member] | Debt Settlement [Member]
Class of Warrant or Right, Issued			295,945
Private Placement [Member] | Series B Preferred Stock [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right, Issued			127,346

Note 3 - Summary of Significa22

Note 3 - Summary of Significant Accounting Policies - Allocation of Consideration Transferred (Details) - Protagenic Therapeutics Inc [Member]	Feb. 12, 2016USD ($)
Total value of shares issued to Atrinsic on Merger	$ 404,169
Fair value of net assets identified
Goodwill	404,169
Common Stock [Member]
Atrinsic	32,334
Preferred Stock [Member] | Series B Preferred Stock [Member]
Atrinsic	$ 371,835

Note 3 - Summary of Significa23

Note 3 - Summary of Significant Accounting Policies - Allocation of Consideration Transferred (Details) (Parentheticals) - Protagenic Therapeutics Inc [Member]	Feb. 12, 2016shares
Common Stock [Member]
Stock Issued During Period, Shares, Reverse Stock Split, Post-split (in shares)	25,867
Preferred Stock [Member] | Series B Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Series A Preferred Stock to Series B Preferred Stock (in shares)	297,468

Note 3 - Summary of Significa24

Note 3 - Summary of Significant Accounting Policies - Assets Measured at Fair Value (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Available-for-sale Securities	$ 1,825,923
Reported Value Measurement [Member]
Available-for-sale Securities	1,825,923
Derivative warrants liabilities	(504,326)	$ (516,870)
Estimate of Fair Value Measurement [Member]
Available-for-sale Securities	1,825,923
Derivative warrants liabilities	(504,326)	(516,870)
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities
Derivative warrants liabilities
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities	1,825,923
Derivative warrants liabilities
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale Securities
Derivative warrants liabilities	$ (504,326)	$ (516,870)

Note 3 - Summary of Significa25

Note 3 - Summary of Significant Accounting Policies - Changes in Fair Value for Assets and Liabilities Measured on a Recurring Basis (Details) - Derivative Financial Instruments, Liabilities [Member]	6 Months Ended
	Jun. 30, 2017USD ($)
Balance, December 31, 2016	$ 516,870
Change in fair value of derivative warrants liabilities	(12,544)
Balance, June 30, 2017	$ 504,326

Note 3 - Summary of Significa26

Note 3 - Summary of Significant Accounting Policies - Weighted Average Assumptions (Details) - $ / shares	Feb. 12, 2016	Jun. 30, 2017	Dec. 31, 2016
Dividend yield		0.00%
Derivative Financial Instruments, Liabilities [Member]
Exercise price (in dollars per share)	$ 1.25	$ 1.25	$ 1.25
Risk free interest rate	1.20%	1.89%	1.93%
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	156.00%	258.40%	219.00%
Contractual term (in years) (Year)	5 years	3 years 182 days	4 years 91 days

Note 3 - Summary of Significa27

Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Common shares issuable under the conversion feature of preferred shares (in shares)	7,212,723	17,437,653
Convertible Preferred Shares [Member]
Common shares issuable under the conversion feature of preferred shares (in shares)	872,766	11,018,766
Employee Stock Option [Member]
Common shares issuable under the conversion feature of preferred shares (in shares)	2,613,299	2,592,229
Warrant [Member]
Common shares issuable under the conversion feature of preferred shares (in shares)	3,726,658	3,826,658

Note 4 - Accounts Payable and28

Note 4 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Legal		$ 1,190
Accounting	13,222
Patent expense		37,142
Research and development	30,970	116,255
Other	29,620	13,400
	$ 73,812	$ 167,987

Note 5 - Derivative Liabiliti29

Note 5 - Derivative Liabilities (Details Textual) - Private Placement [Member] - Series B Preferred Stock [Member]	Feb. 12, 2016$ / sharesshares
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.25
Class of Warrant or Right, Expiration Period	5 years
Strategic Bio Partners [Member] | Debt Settlement [Member]
Class of Warrant or Right, Issued During Period	295,945
Placement Agent Warrants [Member]
Class of Warrant or Right, Issued During Period	127,346

Note 6 - Stockholders' Equity30

Note 6 - Stockholders' Equity (Details Textual)	Jun. 17, 2017	Jan. 01, 2017shares	Feb. 12, 2016USD ($)$ / sharesshares	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number				2,613,299		2,484,445
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | $				$ 193,687		$ 171,537
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				150,000
Class of Warrant or Right, Outstanding, Weighted Average Exercise Price | $ / shares				$ 1.05		$ 1.02
Class of Warrant or Right Outstanding, Aggregate Intrinsic Value | $				$ 763,342
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares				$ 1.25
Class of Warrant or Right, Outstanding				3,726,658		3,826,658
Private Placement [Member] | Series B Preferred Stock [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 1.25
Class of Warrant or Right, Expiration Period			5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			423,291
Protagenic Therapeutics Inc [Member]
Business Combination, Stock Warrant Conversion Ratio			1
Debt Instrument, Face Amount | $			$ 665,000
Debt Instrument, Increase, Accrued Interest | $			$ 35,000
Protagenic Therapeutics Inc [Member] | Predecessor Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 1.25
Class of Warrant or Right, Expiration Period			5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			295,945
Protagenic Therapeutics Inc [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 1.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			127,346
Protagenic Therapeutics Inc [Member] | Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 1.05
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			3,403,367
Employee Stock Option [Member]
Allocated Share-based Compensation Expense | $				$ 500,877	$ 176,892
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $				$ 1,033,921
The 2016 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		564,378
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		2,712,678
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				150,000	1,201,084
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares				$ 1.25	$ 1.25
The 2006 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				0	100,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares				$ 1.25	$ 1.25

Note 6 - Stockholders' Equity -

Note 6 - Stockholders' Equity - Fair Value Assumption (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Expected dividend yield	0.00%	0.00%
Expected life in years (Year)		5 years
Minimum [Member]
Risk free interest rate	1.89%	1.01%
Expected life in years (Year)	4 years 219 days
Expected volatility	204.00%	85.00%
Exercise price (in dollars per share)	$ 1	$ 0.26
Maximum [Member]
Risk free interest rate	2.31%	2.43%
Expected life in years (Year)	9 years 215 days
Expected volatility	258.00%	213.00%
Exercise price (in dollars per share)	$ 1.25	$ 1.25

Note 6 - Stockholders' Equity32

Note 6 - Stockholders' Equity - Stock Option Grant Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Outstanding January 1, 2017 (in shares)	2,484,445
Outstanding, stock options, weighted average exercise price, January 1, 2016 (in dollars per share)	$ 1.18
Outstanding, stock options, weighted average exercise price, December 31, 2016 (in dollars per share)	$ 1.18	$ 1.18
Outstanding, stock options, weighted average remaining contractual life, January 1, 2016 (Year)	7 years 335 days	9 years 299 days
Granted (in shares)	150,000
Granted, stock options, weighted average exercise price (in dollars per share)	$ 1.25
Granted, stock options, weighted average remaining contractual life (Year)	4 years 40 days
Expired (in shares)	(21,146)
Expired, stock options, weighted average exercise price (in dollars per share)	$ 1
Outstanding June 30, 2017 (in shares)	2,613,299	2,484,445

Note 6 - Stockholders' Equity33

Note 6 - Stockholders' Equity - Summary of Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Outstanding (in shares)	3,826,658
Outstanding, weighted average exercise price (in dollars per share)	$ 1.02
Outstanding, weighted average exercise price (in dollars per share)	$ 1.05	$ 1.02
Outstanding, weighted average remaining life (Year)	5 years 94 days	5 years 262 days
Expired (in shares)	100,000
Expired, weighted average exercise price (in dollars per share)	$ 1.25
Outstanding (in shares)	3,726,658	3,826,658

Note 7 - Collaborative Agreem34

Note 7 - Collaborative Agreements (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		39 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017
Research and Development Expense	$ 120,180	$ 290,577	$ 258,992	$ 227,812
In Process Research and Development [Member]
Research and Development Expense			$ 20,233.34	$ 3,000
University of Toronto [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures					25,000
University of Toronto [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
University of Toronto [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 1		$ 1		$ 1
Professor [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					275,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures					483,299
Professor [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 1		$ 1		$ 1
Professor [Member] | Maximum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					13 years
Professor [Member] | Minimum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years

Note 8 - Licensing Agreements (

Note 8 - Licensing Agreements (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Feb. 18, 2015
Royalty Payment on Behalf of Sub-licensee, Percentage					2.50%
Revenues	$ 0	$ 0	$ 0	$ 0
Licensing Agreements [Member]
Royalty Payment, Percentage					2.50%
Up-front Sub-license Fees, Percentage					10.00%

Note 9 - Commitments and Cont36

Note 9 - Commitments and Contingencies (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	21,146
Officer [Member] | Employment Agreement [Member]
Monthly Salary Agreement Amount		$ 6,489
Compensation	$ 12,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures		75,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Value		$ 64,223
Allocated Share-based Compensation Expense		$ 53,519
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number		250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period		25,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		225,000
Increase (Decrease) in Accrued Salaries	0
Officer [Member] | Employment Agreement [Member] | Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price		$ 1
Officer [Member] | Employment Agreement [Member] | Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price		$ 1.25
Stockholder [Member] | Consulting Agreement [Member]
Compensation	$ 13,493
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	150,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Compensation of Rendered Service	$ 2,370
Increase (Decrease) in Accrued Salaries	$ 0
Stockholder [Member] | Consulting Agreement [Member] | Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 1
Stockholder [Member] | Consulting Agreement [Member] | Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 1.25